TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20132927

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 104

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Smoking (both nicotine and denicotinized)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Smoking reinforcement
Number of subjects: 104
Study: 18594318

Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex (PPX) 175 mg/m
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (single-agent vinorelbine or gemcitabine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex (PPX)
Number of subjects: 0
Study: 16403289

Group type: EXPERIMENTAL
Intervention: Cationic propyl gallate (C‐PG) at 100‐300 micromol/L
Number of subjects: 516

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) at 200‐400 mg
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Cationic propyl gallate (C‐PG) as inducer of platelet aggregation
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Activated plasma clotting time (APCT) examination
Number of subjects: 516
Study: 12186195

Group type: EXPERIMENTAL
Intervention: Hospitalization advice by primary care providers
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hospitalization advice for older infants
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Parenteral antibiotics prescription
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hospital admission after advice
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hospital admission refusal
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Mortality after hospitalization
Number of subjects: 162
Study: 10822908

Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate solutions (HFG, LFG, GLU, BAN, SUG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate and/or electrolytes in hydration solutions
Number of subjects: 10
Study: 8856384

Group type: EXPERIMENTAL
Intervention: Inflamed skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heated inflamed skin (44 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cuff occlusion method (same skin temperature)
Number of subjects: 0
Study: 1628294

Group type: COMPARATOR
Intervention: Active control agent
Number of subjects: 6
Study: 6230217

Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 110
Study: 31294619

Group type: EXPERIMENTAL
Intervention: Diphencyprone immunotherapy with intralesional meglumine antimoniate (MA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (MA) alone
Number of subjects: 46
Study: 30489151

Group type: EXPERIMENTAL
Intervention: DiLEP
Number of subjects: 157
Study: 29722481

Group type: EXPERIMENTAL
Intervention: Web-delivered physical activity intervention (educational materials, activity monitor, interactive website)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (activity monitor and educational materials)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Web-delivered physical activity intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 26460571

Group type: EXPERIMENTAL
Intervention: 15-min brief advice (BA) session
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: 60- to 90-min brief motivational intervention (BMI)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Assessment only (AO) control
Number of subjects: 598
Study: 25273912

Group type: EXPERIMENTAL
Intervention: losartan/hydrochlorothiazide (HCTZ)
Number of subjects: 94

Group type: COMPARATOR
Intervention: maximum doses of ARB
Number of subjects: 94
Study: 22850442

Group type: EXPERIMENTAL
Intervention: 2.5 mg of rosuvastatin
Number of subjects: 51

Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 51
Study: 20440152

Group type: COMPARATOR
Intervention: Quilting sutures only (group 1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of Quixil sealant and marginal quilting sutures (group 2)
Number of subjects: 26
Study: 18537963

Group type: EXPERIMENTAL
Intervention: Midazolam IV (2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam oral (7.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1'-hydroxymidazolam IV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1'-hydroxymidazolam oral
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Correlation between midazolam concentrations in plasma and saliva
Number of subjects: 8
Study: 15944167

Group type: EXPERIMENTAL
Intervention: SMC + CBT
Number of subjects: 69

Group type: COMPARATOR
Intervention: SMC
Number of subjects: 69
Study: 11906339

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (ATCC 53103) for 5.5 months (2.5 months before, 1 month during, and 2 months after the birch-pollen season)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10364646

Group type: EXPERIMENTAL
Intervention: Volumetric magnetic resonance imaging assessment of the hippocampal region
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (25 members)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Volumetric magnetic resonance imaging assessment
Number of subjects: 50
Study: 7729304

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Non-digoxin
Number of subjects: 2000
Study: 1781045

Group type: EXPERIMENTAL
Intervention: Breast conservation (tumor excised with tumor-free margins and subsequent radiotherapy)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Mastectomy (modified radical procedure with axilla dissection)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Breast conservation
Number of subjects: 905

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Non-randomized group (breast conservation)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Non-randomized group (mastectomy)
Number of subjects: 905
Study: 7010161

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 77

Group type: COMPARATOR
Intervention: Oxymetholone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Fluoxymesterone
Number of subjects: 77
Study: 30628526

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise therapy with bracing for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scientific Exercises Approach to Scoliosis with bracing for 4 months
Number of subjects: 30
Study: 28866370

Group type: EXPERIMENTAL
Intervention: Direct Inhibitory Pressure (DIP) on the biceps brachii myotendinous junction (10‐s pressure) with elbow at 120° (DIP120)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Direct Inhibitory Pressure (DIP) on the biceps brachii myotendinous junction (10‐s pressure) with elbow at 180° (DIP180)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No Direct Inhibitory Pressure (Control)
Number of subjects: 35
Study: 25739842

Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation (n = 26)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Shoulder thrust manipulation (n = 27)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Shoulder exercise (n = 25)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Healthy control group (n = 25)
Number of subjects: 78
Study: 23813218

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA; target trough level of 80-100 ng/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 60
Study: 20970946

Group type: EXPERIMENTAL
Intervention: ASMA‐Undx (intervention group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 30
Study: 19203567

Group type: EXPERIMENTAL
Intervention: i.v. flumazenil 0.005 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: i.v. flumazenil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: midazolam exposure
Number of subjects: 16
Study: 18077945

Group type: EXPERIMENTAL
Intervention: 40 mg of oral pravastatin daily for 14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15612962

Group type: EXPERIMENTAL
Intervention: Funhaler spacer device
Number of subjects: 32

Group type: COMPARATOR
Intervention: Existing low volume spacer device
Number of subjects: 32
Study: 12219805

Group type: EXPERIMENTAL
Intervention: Bubbles method for visual information recognition
Number of subjects: 0
Study: 9640557

Group type: EXPERIMENTAL
Intervention: Regular AHA-blend cream
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Extra strength AHA-blend cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control: non-AHA moisturizing lotion
Number of subjects: 20
Study: 9922479

Group type: EXPERIMENTAL
Intervention: UDCA 300 mg per day (group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: UDCA 150 mg per day (group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Solitary MCL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple MCL
Number of subjects: 30
Study: 1833165

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20-40 mg/day) for 24 months
Number of subjects: 134

Group type: COMPARATOR
Intervention: Captopril (75-150 mg/day) for 24 months
Number of subjects: 134
Study: 6136841

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg every 6 h from 8 days before to 35 days after bone-marrow transplantation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28370716

Group type: EXPERIMENTAL
Intervention: Sleep Position Trainer
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study: 26748541

Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Reactive telephone counselling
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Internet- and text-message-based intervention
Number of subjects: 1808

Group type: COMPARATOR
Intervention: Self-help booklet (control)
Number of subjects: 1808
Study: 24553304

Group type: EXPERIMENTAL
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study: 22929301

Group type: EXPERIMENTAL
Intervention: Triple touch immobilization (TTIm)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Single touch immobilization (STIm)
Number of subjects: 290
Study: 20717839

Group type: EXPERIMENTAL
Intervention: In vitro models of AZD0865
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theoretical model for AZD0865
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical studies of AZD0865
Number of subjects: 0
Study: 17638305

Group type: EXPERIMENTAL
Intervention: RTX 50 nM
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15830402

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11934348

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 0
Study: 9059200

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline 1 ml
Number of subjects: 30
Study: 8437966

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3527321

Group type: EXPERIMENTAL
Intervention: Oral ursodeoxycholic acid for 48 h before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 40
Study: 29885745

Group type: EXPERIMENTAL
Intervention: autoVMAT plans
Number of subjects: 725

Group type: COMPARATOR
Intervention: CLINICAL plans
Number of subjects: 725
Study: 26596974

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg IV once daily
Number of subjects: 153

Group type: COMPARATOR
Intervention: Itraconazole 200 mg IV once daily
Number of subjects: 153
Study: 25001269

Group type: EXPERIMENTAL
Intervention: Trimetaphan (4 mg/min IV, autonomic blocked day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (intact day)
Number of subjects: 21
Study: 22566392

Group type: EXPERIMENTAL
Intervention: External neck brace (ENB 1.0)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No external neck brace
Number of subjects: 28
Study: 20131090

Group type: EXPERIMENTAL
Intervention: Suppression of pain-related thoughts and feelings during cold pressor
Number of subjects: 222

Group type: COMPARATOR
Intervention: No Suppression condition
Number of subjects: 222
Study: 18377124

Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral therapy (ICBT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Family cognitive‐behavioral therapy (FCBT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Family-based education/support/attention (FESA)
Number of subjects: 161
Study: 16210884

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 40
Study: 14641611

Group type: EXPERIMENTAL
Intervention: SIT (grass or birch) + anti‐IgE
Number of subjects: 19

Group type: COMPARATOR
Intervention: SIT (grass or birch) + placebo
Number of subjects: 19
Study: 10594562

Group type: EXPERIMENTAL
Intervention: benznidazole therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 8911861

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 1 microgram i.v. alone and as pretreatment to oCRH (1 microgram kg‐1 BW i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Desmopressin (DDAVP) as pretreatment to oCRH in normal subjects
Number of subjects: 8
Study: 1736755

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (2 ml/kg of 50% vodka)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (room air or air/oxygen mixture)
Number of subjects: 10
Study: 6371236

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study: 30686750

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29397850

Group type: EXPERIMENTAL
Intervention: rhTPO (15000 IU/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: rhIL-11 (1.5 mg/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study: 26803443

Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (1×10^13 DNase-resistant particles)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 24114310

Group type: EXPERIMENTAL
Intervention: Dismissing children
Number of subjects: 106

Group type: COMPARATOR
Intervention: Secure children
Number of subjects: 106
Study: 22399248

Group type: COMPARATOR
Intervention: PegIFN/RBV
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mosapride (15 mg/person/day) with PegIFN/RBV
Number of subjects: 24
Study: 19887462

Group type: EXPERIMENTAL
Intervention: Intensive protocol-based strategy involving bi-weekly visits for 16 weeks with medication adjustments as needed.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 156
Study: 17699009

Group type: EXPERIMENTAL
Intervention: Western dietary pattern (highest quintile)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Prudent dietary pattern
Number of subjects: 1009
Study: 16120136

Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 11999090

Group type: EXPERIMENTAL
Intervention: Coronary heart disease prevalence diagnosed by history or ECG changes
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Smoking/tobacco use
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Hypertension (> or =140 and/or 90 mmHg)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Diabetes (history or fasting glucose > or =126 mg/dl)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > or =27 kg/m2)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Truncal obesity (waist:hip >0.9 males, >0.8 females)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Dyslipidemia (low HDL-cholesterol <40 mg/dl)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: High total cholesterol (> or =200 mg/dl)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: High LDL-cholesterol (> or =130 mg/dl)
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: High triglycerides (> or =150 mg/dl)
Number of subjects: 1123
Study: 9620811

Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery (ONDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 0
Study: 7611593

Group type: EXPERIMENTAL
Intervention: Patients with cirrhosis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study: 1692926

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 8
Study: 183084

Group type: EXPERIMENTAL
Intervention: Cholestyramine therapy with a low cholesterol diet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Out-patient follow-up designed to reinforce patient motivation and dietary and drug adherence
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inpatient studies
Number of subjects: 16
Study: 31406538

Group type: COMPARATOR
Intervention: Intranasal steroids, antihistamines, leukotriene antagonists (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser acupuncture sessions (12 sessions, 2 sessions per week on specific acupuncture points) (Group 2)
Number of subjects: 60
Study: 26188833

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg combined with Simvastatin 10 mg (Vyto10)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg combined with Simvastatin 20 mg (Vyto20)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg alone (Simva20)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 23328284

Group type: EXPERIMENTAL
Intervention: Lactulose treatment (n = 32)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Live binary Bacillus subtilis treatment (n = 31)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Combined treatment (n = 34)
Number of subjects: 97
Study: 19926201

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Laparoscopically Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 125
Study: 18190369

Group type: EXPERIMENTAL
Intervention: Early feeding (regular diet within the first 8 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed feeding (oral fluids 4 hours after surgery, diet at 24 hours)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed feeding
Number of subjects: 200
Study: 15673875

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg IM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 12 mg IM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 6 mg IM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active treatment groups (Parecoxib sodium and morphine)
Number of subjects: 0
Study: 12560309

Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.5 MAC desflurane
Number of subjects: 16
Study: 10589357

Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporine (CSA) and methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study: 7847432

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 1940189

Group type: EXPERIMENTAL
Intervention: Maalox TC (1 tablet q.i.d., acid neutralizing capacity of 104 mEq/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6210686

Group type: EXPERIMENTAL
Intervention: 1 g iv dose of mezlocillin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5 g iv dose of mezlocillin
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1 g dose during haemodialysis (HD)
Number of subjects: 22
Study: 31103344

Group type: EXPERIMENTAL
Intervention: Circulating phylloquinone
Number of subjects: 103097

Group type: EXPERIMENTAL
Intervention: Dephosphorylated uncarboxylated Matrix Gla Protein (dp-ucMGP)
Number of subjects: 103097
Study: 29654841

Group type: EXPERIMENTAL
Intervention: Verum Acupuncture (VA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acupressure (AP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Acupuncture (CA)
Number of subjects: 18
Study: 27995880

Group type: EXPERIMENTAL
Intervention: Generic dasatinib (100 mg dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference dasatinib (100 mg dose)
Number of subjects: 12
Study: 25409454

Group type: EXPERIMENTAL
Intervention: Personalised feedback on alcohol intake and feedback on other health behaviours (n=659)
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Feedback on all health behaviours except alcohol intake (n=671)
Number of subjects: 1330
Study: 23326976

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 112
Study: 20804269

Group type: EXPERIMENTAL
Intervention: Telephone-administered psychotherapy for depression (16 weeks)
Number of subjects: 102
Study: 18978165

Group type: EXPERIMENTAL
Intervention: 15 mg zinc gluconate/d
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 30 mg zinc gluconate/d
Number of subjects: 387

Group type: COMPARATOR
Intervention: 0 mg zinc gluconate/d (placebo)
Number of subjects: 387